Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disorder without effective neuroprotective therapy. Known genetic variants impair pathways including RNA processing, axonal transport and protein homeostasis. Here we report mutations in a new ALS gene encoding the glycosyltransferase GLT8D1; this class of proteins has not previously been associated with neurodegeneration. Exome sequencing in an autosomal dominant ALS pedigree identified p.R92C mutations in GLT8D1 which co-segregate with disease. Sequencing of local and international cohorts demonstrated significant ALS-association in the same exon, including additional rare deleterious mutations in conserved amino acids. Mutations are associated with the substrate binding site and R92C reduces GLT8D1 enzyme activity ~2-fold. Mutated GLT8D1 exhibits in vitro cytotoxicity and induces motor deficits in zebrafish consistent with ALS. Relative toxicity of mutations in model systems mirrors clinical severity. In conclusion, we have discovered a previously uncharacterised pathophysiological pathway for ALS caused by inherited mutations within a glycosyltransferase enzyme.
Cooper-Knock, Johnathan and Moll, Tobias and Ramesh, Tennore and Castelli, Lydia and Beer, Alexander and Robins, Henry and Fox, Ian and Niedermoser, Isabell and Van Damme, Philip and Robberecht, Wim and Hardiman, Orla and Panades, Monica P. and Mora, Jesús S. and Basak, A. Nazli and Morrison, Karen E. and Shaw, Christopher E. and Al-Chalabi, Ammar and Landers, John E. and Wyles, Matthew and Heath, Paul R. and Higginbottom, Adrian and Walsh, Theresa and Kazoka, Mbombe and McDermott, Christopher J. and Hautbergue, Guillaume M. and Kirby, Janine and Shaw, Pamela J., Mutations in the Glycosyltransferase Domain of GLT8D1 Cause Amyotrophic Lateral Sclerosis (September 6, 2018). Available at SSRN: https://ssrn.com/abstract=3245222 or http://dx.doi.org/10.2139/ssrn.3245222
This version of the paper has not been formally peer reviewed.